Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IMMP
IMMP logo

IMMP News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

IMMP News

Immutep Faces Class Action Lawsuit for Securities Violations

1d agoGlobenewswire

Immutep Securities Fraud Class Action Reminder

2d agoGlobenewswire

Immutep Faces Class Action Lawsuit, Stock Price Plummets

3d agoGlobenewswire

Immutep Investors Face Class Action Lawsuit Over TACTI-004 Trial Failures

3d agoGlobenewswire

Immutep Faces Class Action Lawsuit for Securities Violations

4d agoGlobenewswire

Immutep Faces Class Action Lawsuit Over Securities Fraud Allegations

5d agoGlobenewswire

Immutep Limited Faces Investor Misleading Allegations

Jun 10 2026PRnewswire

Immutep Faces Class Action Lawsuit for Securities Violations

Jun 09 2026Globenewswire

IMMP Events

06/04 09:20
Immutep Presents First Clinical Data for IMP761 at Rheumatology Congress
Immutep announced it will present first-in-human clinical data for its lead autoimmune candidate, IMP761, at the European Alliance of Associations for Rheumatology Congress. Initial clinical findings showed significant and clinically relevant pharmacodynamic activity, including reduction of local inflammatory responses and attenuated T-cell activity compared to placebo. "I am very excited about this first clinical evaluation of IMP761. IMP761 is designed to selectively target overactive T cells linked to chronic inflammation and is now showing clear immunosuppressive effects at dose levels above 0.9 mg/kg in this placebo controlled Phase I study. IMP761 could be positioned to address significant unmet need across multiple autoimmune indications such as rheumatoid arthritis or other T cell driven conditions," said Frederic Triebel, CSO of Immutep.
05/22 12:10
Major Averages Rise as Markets Watch Iran Negotiations
The major averages were broadly higher near noon as markets head toward a weekly gain despite continued volatility. Treasury yields have eased, lifting megacaps and chip stocks, though markets continue to be on watch for signs of a breakthrough in negotiations to end the war in Iran.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Estee Lauderand Puigannounced that the partiesregarding a potential business combinationImaxis exploring a sale, according toWorkdayreportedand reiterated its FY27 revenue guidanceZoom Communicationsprovided areport for Q1Deckers Outdoorreportedand provided its outlook for FY272. WALL STREET CALLS:JPMorganSweetgreenon ramping brand transformationViking Holdingsto Buy at Truist on strong demand trendsJefferiesGeneracon data center contract potentialSummit Therapeuticsto Neutral at H.C. WainwrightInspire Medicalto Underperform at BofA on coding overhang3. AROUND THE WEB:Nintendo's"Tomodachi Life: Living the Dream" was the top-selling physical video game in Japan for the week of May 11-17 with 98,092 copies sold during the week, bringing the game's lifetime sales in Japan to 1.14M, Famitsu reportsSony'sBungie plans to lay off a significant number of workers as it concludes active development on "Destiny 2," Bloomberg saysMicrosoftcommercial chief marketing officer Yusuf Mehdi, a 35-year company veteran, is set to depart after the next fiscal year according to an internal memo, Business Insider reportsStarbucksshut down an AI program for automating inventory counts, nine months after deploying it, after it frequently miscounted and mislabeled items, Reuters saysSamsungis set to distribute about $26.6B to its 78,000 chip employees, or a $340,000 bonus to each, in early 2027 as part of a last-minute labor union deal, Bloomberg reports4. MOVERS:Pelotongains after beingin the S&P 600Rocket Labsincreases after completing itsfor SynspectiveFutu Holdingsand UP Fintechfall in New York afterChina has launched a broad crackdown on unauthorized cross-border investingCAElower in New York afterand setting long-term financial targets for FY30ImmunityBiodeclines afteron NMIBC and presenting preliminary results from a new health economic analysis on that ANKTIVA plus Bacillus Calmette-Guerin5. EARNINGS/GUIDANCE:BJ's Wholesaleand backed its guidance for FY26 after what CEO Bob Eddy called "a strong first quarter"Take-Two, with EPS missing consensusBooz Allenand provided guidance for FY27Ross Stores, with EPS and revenue beating consensusGlobal Ship Lease (GSL), with EPS lower year-over-yearINDEXES:Near midday, the Dow was up 0.81%, or 408.71, to 50,694.37, the Nasdaq was up 0.63%, or 164.99, to 26,458.08, and the S&P 500 was up 0.66%, or 49.08, to 7,494.80.
05/22 10:40
Company Reports Q1 Revenue of $61.7M
Reports Q1 revenue $61.7M vs $32M last year. CEO Harry Vafias Commented, "We are extremely pleased with our first quarter 2026 results. With a net income of $28 million, corresponding to a basic EPS of $0.60 per share, we generated the second-best quarterly profitability in the Company's history. Geopolitical tensions persist, creating turbulence across global markets and the shipping industry in particular. The ongoing Middle East conflict has driven tanker market rates to peak levels, while dry bulk market rates have also firmed"

IMMP Monitor News

Immutep faces legal scrutiny amid securities claims investigation

Apr 15 2026

Immutep Ltd Hits 52-Week High on Licensing Deal

Dec 08 2025

IMMP Earnings Analysis

No Data

No Data

People Also Watch